From the Unified Patent Court to life sciences industrial strategy, there are many issues for Sean Dennehey to contend with as deputy CEO of the UK Intellectual Property Office. He talks to LSIPR about how he managed.
2016 was a tumultuous year. Not only did the UK vote to leave the EU, but the UK Intellectual Property Office (IPO) lost its CEO and two experienced directors.
But with Sean Dennehey at the helm of the IPO, things ran smoothly.
Dennehey took on the role of acting CEO after replacing former chief John Alty, who was appointed director general of trade policy in the Department for International Trade in July last year. In May 2017, Dennehey became deputy CEO after Tim Moss was appointed to lead the office.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
Sean Dennehey, UK Intellectual Property Office, deputy director, Unified Patent Court, industrial strategy